Anti-beta2-glycoprotein I antibodies and ischemic stroke in a 20-month-old boy

Eustathia Katsarou1, Achilleas Attilakos, Smaragdi Fessatou

  • 1Department of Neurology, Panagiotis and Aglaïa Kyriakou Children's Hospital, Athens, 11527 Greece. pectasid@otenet.gr

Pediatrics
|July 3, 2003
PubMed

Insights

This study reports the first case of childhood ischemic stroke linked solely to antibodies to beta2-glycoprotein I (anti-beta2GPI), even when standard antiphospholipid tests were negative. It highlights the importance of testing for anti-beta2GPI in children with suspected antiphospholipid syndrome.

Area of Science:

  • Pediatric Neurology
  • Immunology
  • Vascular Medicine

Background:

  • Antibodies to beta2-glycoprotein I (anti-beta2GPI) are linked to thrombosis and pregnancy issues.
  • The prevalence of anti-beta2GPI in pediatric cerebral infarction is not well-established.
  • Antiphospholipid syndrome (APS) is a significant cause of stroke in children.

Observation:

  • A 20-month-old boy experienced an ischemic stroke.
  • High immunoglobulin G anti-beta2GPI titers were detected.
  • Standard antiphospholipid assays, including anticardiolipin antibodies and lupus anticoagulant tests, were negative.
  • Other causes of cerebral infarction were ruled out.

Findings:

  • This case represents the first documented instance of childhood ischemic stroke associated exclusively with anti-beta2GPI.
  • The patient demonstrated persistently high anti-beta2GPI IgG levels over two years.
  • Treatment with low-dose aspirin was initiated.

Implications:

  • This case underscores the necessity of screening for anti-beta2GPI in pediatric patients with suspected APS, especially when conventional antiphospholipid antibody tests are negative.
  • It supports broader diagnostic criteria for APS in children presenting with ischemic events.
  • Early detection and management of anti-beta2GPI-associated conditions can potentially prevent recurrent thrombotic events in children.